CDC Releases Updated Recommendations for Treatment of Latent TB Infection

Having trouble viewing this email? View it as a Web page.
Bookmark and Share

TB Banner

NEW: Update on Recommendations for Use of Once-weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium Tuberculosis Infection

Dear Colleagues:

CDC has updated the 2011 recommendations for use of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for treatment of latent TB infection.

TB Recommendation 2

The updated recommendations, published in CDC’s Morbidity and Mortality Weekly Report (MMWR) support and expand the use of an effective, yet shorter treatment regimen to reach even more people with latent TB infection.  The updated recommendations include: 

o   use of 3HP by directly observed therapy or self-administered therapy in persons over 2 years of age;
o   use of 3HP in persons 2-11 years old; and
o   use of 3HP in persons with latent TB infection who are living with HIV/AIDS and taking antiretroviral medications with acceptable drug-drug interactions with rifapentine.

Short course regimens, like 3HP, are preferred for reasons of convenience and higher rates of treatment completion. Treatment of latent TB infection is essential to controlling and eliminating TB in the United States because it substantially reduces the risk that latent TB infection will progress to TB disease.

TB Regimen 2

CDC has new resources and tools for clinicians and patients to download and print.

Patient Education Materials:

Clinician Resources:

Be sure to check the website for more information.  You can also follow us on Twitter @CDC_TB and Facebook @CDCTB 

Thank you,

Division of Tuberculosis Elimination

U.S. Centers for Disease Control and Prevention

Call to Action
                                                        Find More Information on 3HP

TB FAQs 2

Read the MMWR article, Update on Recommendations for Use of Once-weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.

Read the American Journal of Preventive Medicine, Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-Analysis.

Social Networking

Share on Twitter

Twitter Logo

• CDC has updated the recommendations for the 12-dose treatment for latent #TB infection. Get the details from @CDCMMWR: https://go.usa.gov/xUagH

• Help eliminate #tuberculosis in the United States by treating latent #TB infection.  See updated recommendations for the 12-dose regimen in @CDCMMWR: https://go.usa.gov/xUagH

 

Share on Facebook

FBook Logo

• CDC has updated the recommendations to treat latent #TB infection in 12 doses.  To eliminate #tuberculosis in the United States we need to treat latent #TB infection to prevent progression to #TB disease.  Get more information in @CDCMMWR:  https://go.usa.gov/xUagH

• Treating latent TB infection prevents TB disease.  CDC has expanded its recommendations for the 12-dose treatment regimen for latent TB infection.  Get more information in @CDCMMWR: https://go.usa.gov/xUagH

Social Media Graphics

Download and share our social media graphics.

 

Contact information in the bottom corner

You can follow us on Twitter @CDC_TB and Facebook @CDCTB and sign up for email updates through GovDelivery.

footer

 

You are receiving this Special Announcement because you are a stakeholder of the Centers for Disease Control and Prevention (CDC). CDC has requested that you be included in the recipients of this message and therefore there is no unsubscribe option. For questions about this list, please contact CDC NPIN at NPIN-info@cdc.gov.